Acute Prolongation of Myocardial Refractoriness by Sotalol

Overview

Journal Br Heart J

Specialty Cardiology & Vascular Diseases

Date 1982 Jun 1

PMID 7082500

Citations 11

Authors

D H Bennett

Affiliations

Soon will be listed here.

Abstract

Sotalol, a beta adrenoceptor antagonist, was given intravenously to 15 patients with accessory atrioventricular pathways during intracardiac electrophysiological studies. Eleven patients had the Wolff-Parkinson-White syndrome and four patients had concealed left sided accessory pathways. Four patients were restudied while receiving oral sotalol. In contrast to the actions typical of beta blocking agents, intravenous sotalol prolonged the effective refractory periods of the ventricles and accessory pathways and reduced the ventricular response to atrial fibrillation in the patients with the Wolff-Parkinson-White syndrome. Similar results were obtained with oral administration. These findings support the observation that sotalol, unlike other beta blocking agents. causes acute prolongation of the myocardial action potential and suggest that this action might be of therapeutic use.

Citing Articles

Effect of low dose sotalol on the signal averaged P wave in patients with paroxysmal atrial fibrillation.

Stafford P, Cooper J, De Bono D, Vincent R, Garratt C Br Heart J. 1995; 74(6):636-40.

PMID: 8541169 PMC: 484120. DOI: 10.1136/hrt.74.6.636.

Sotalol, hypokalaemia, syncope, and torsade de pointes.

McKibbin J, POCOCK W, BARLOW J, Millar R, Obel I Br Heart J. 1984; 51(2):157-62.

PMID: 6197982 PMC: 481476. DOI: 10.1136/hrt.51.2.157.

A comparison of the cardiovascular effects of (+)-sotalol and (+/-)-sotalol following intravenous administration in normal volunteers.

Johnston G, Finch M, McNEILL J, Shanks R Br J Clin Pharmacol. 1985; 20(5):507-10.

PMID: 4074623 PMC: 1400709. DOI: 10.1111/j.1365-2125.1985.tb05109.x.

The prolonged QT interval--a frequently unrecognized abnormality.

Kenny R, Sutton R Postgrad Med J. 1985; 61(715):379-86.

PMID: 4022873 PMC: 2418254. DOI: 10.1136/pgmj.61.715.379.

Cellular electrophysiological effects of D- and DL-sotalol in guinea-pig sinoatrial node, atrium and ventricle and human atrium: differential tissue sensitivity.

Campbell T Br J Pharmacol. 1987; 90(3):593-9.

PMID: 3567463 PMC: 1917192. DOI: 10.1111/j.1476-5381.1987.tb11210.x.

References

Singh B, VAUGHAN WILLIAMS E . The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol. 1970; 39(4):657-67. PMC: 1702721. DOI: 10.1111/j.1476-5381.1970.tb09891.x. View

Singh B, VAUGHAN WILLIAMS E . A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol. 1970; 39(4):675-87. PMC: 1702723. DOI: 10.1111/j.1476-5381.1970.tb09893.x. View

Spurrell R, Krikler D, Sowton E . Concealed bypasses of the atrioventricular mode in patients with paroxysmal supraventricular tachycardia revealed by intracardiac electrical stimulation and verapamil. Am J Cardiol. 1974; 33(5):590-5. DOI: 10.1016/0002-9149(74)90247-1. View

ROSENBAUM M, Chiale P, Ryba D, Elizari M . Control of tachyarrhythmias associated with Wolff-Parkinson-White syndrome by amiodarone hydrochloride. Am J Cardiol. 1974; 34(2):215-23. DOI: 10.1016/0002-9149(74)90200-8. View

Seides S, Josephson M, Batsford W, Weisfogel G, Lau S, DAMATO A . The electrophysiology of propranolol in man. Am Heart J. 1974; 88(6):733-41. DOI: 10.1016/0002-8703(74)90283-x. View

Williams E, Raine A, Cabrera A, Whyte J . The effects of prolonged beta-adrenoceptor blockade on heart weight and cardiac intracellular potentials in rabbits. Cardiovasc Res. 1975; 9(5):579-92. DOI: 10.1093/cvr/9.5.579. View

Sellers Jr T, CAMPBELL R, Bashore T, Gallagher J . Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome. Circulation. 1977; 55(1):15-22. DOI: 10.1161/01.cir.55.1.15. View

ROSENBAUM M, Chiale P, Halpern M, Nau G, Przybylski J, Levi R . Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol. 1976; 38(7):934-44. DOI: 10.1016/0002-9149(76)90807-9. View

Di Biase M, Brindicci G, Rizzon P . Effects of prindolol on impulse formation and conduction in man. J Electrocardiol. 1977; 10(1):45-50. DOI: 10.1016/s0022-0736(77)80030-7. View

10.

Gallagher J, Pritchett E, SEALY W, Kasell J, Wallace A . The preexcitation syndromes. Prog Cardiovasc Dis. 1978; 20(4):285-327. DOI: 10.1016/0033-0620(78)90015-4. View

11.

Robinson C, Birkhead J, Crook B, Jennings K, Jewitt D . Clinical electrophysiological effects of atenolol--a new cardioselective beta-blocking agent. Br Heart J. 1978; 40(1):14-21. PMC: 481968. DOI: 10.1136/hrt.40.1.14. View

12.

Denes P, CUMMINGS J, Simpson R, Wu D, Dhingra R, Rosen K . Effects of propranolol on anomalous pathway refractoriness and circus movement tachycardias in patients with preexcitation. Am J Cardiol. 1978; 41(6):1061-7. DOI: 10.1016/0002-9149(78)90858-5. View

13.

Bennett D . Disopyramide in patients with the Wolff-Parkinson-White syndrome and atrial fibrillation. Chest. 1978; 74(6):624-8. DOI: 10.1378/chest.74.6.624. View

14.

Ward D, Camm A, Spurrell R . The acute cardiac electrophysiological effects of intravenous sotalol hydrochloride. Clin Cardiol. 1979; 2(3):185-91. DOI: 10.1002/clc.4960020303. View

15.

Edvardsson N, Olsson S . Effects of acute and chronic beta-receptor blockade on ventricular repolarisation in man. Br Heart J. 1981; 45(6):628-36. PMC: 482575. DOI: 10.1136/hrt.45.6.628. View

16.

Edvardsson N, Hirsch I, Emanuelsson H, Ponten J, Olsson S . Sotalol-induced delayed ventricular repolarization in man. Eur Heart J. 1980; 1(5):335-43. DOI: 10.1093/eurheartj/1.5.335. View

17.

Neuvonen P, Elonen E . Sotalol, prolonged Q-Tc interval, and tachyarrhythmias. Lancet. 1982; 1(8263):106. DOI: 10.1016/s0140-6736(82)90241-0. View